Navigation Links
HIV integrase inhibitor effective for patients beginning antiretroviral treatment
Date:8/2/2009

A member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV, according to researchers who have completed a two-year multisite phase III clinical trial comparing it with standard antiretroviral drugs.

The results are online and scheduled for publication in an upcoming issue of the Lancet.

Lead author of the Lancet article is Jeffrey Lennox, MD, professor of medicine (infectious diseases) at Emory University School of Medicine. Lennox is chief of Emory's HIV/AIDS clinical trials unit and vice-chair of medicine dealing with Grady Memorial Hospital.

"These results provide an additional potent, well tolerated treatment option for newly diagnosed patients with HIV infection," says Lennox.

Raltegravir, a HIV integrase inhibitor, is overall as effective as widely used efavirenz, a reverse transcriptase inhibitor, the researchers found. Raltegravir also had faster onset of action and fewer adverse side effects. In the clinical trial, both were combined with two other standard retroviral drugs, tenofovir and emtricitabine.

The trial included 566 patients from 67 medical centers on five continents. The "primary endpoint" of the trial was pushing viral levels below 50 copies per ml of blood by week 48. Of the raltegravir group, 86 percent reached that goal, compared with 82 percent of the efavirenz group.

Half the raltegravir group reached the endpoint by week four, compared with less than 20 percent for the efavirenz group. In addition, the raltegravir group encountered fewer side effects such as headache, dizziness and elevation in levels of cholesterol.

Raltegravir inhibits the HIV integrase enzyme, which inserts the viral genome into the host cell's DNA. It was the first integrase inhibitor to be approved by the FDA. Other types of antiretroviral drugs inhibit HIV's protease or reverse transcriptase enzymes.

Guidelines from the U.S.
'/>"/>

Contact: Sarah Goodwin
sgoodwi@emory.edu
404-727-3366
Emory University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. Silencing small but mighty cancer inhibitors
6. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
7. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
8. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
9. Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer
10. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
11. ACE Inhibitor as Effective as More Expensive Blood Pressure Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... York (PRWEB) July 13, 2014 Intraocular ... Trends and Forecast 2013 - 2019 , Intraocular lens ... suffering from myopia or cataracts. The lenses are inserted ... the cataract surgery intraocular lens replaces the focusing power ... with original crystalline lens to deliver the light focusing ...
(Date:7/13/2014)... in Nature Genetics identifies a novel ... causes eosinophillic esophagitis (EoE), opening up potential new ... allergy. , EoE is a chronic inflammatory ... by allergic hypersensitivity to certain foods and an ... called eosinophils (part of the body,s immune system). ...
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... 13, 2014 Chromatography system is ... from various types of biological samples such as ... sample mixture into two phase, namely mobile phase ... phase run over the stationary phase, followed by ... that provide the separation of mixture. Chromatography system ...
(Date:7/13/2014)... July 13, 2014 Recently, MillionaireCasket.com, a well-known ... oak caskets . Additionally, the company’s chief executive officer ... the new oak caskets are offered at discounted prices, from ... am concerned, quality caskets are in huge demand in the ... caskets . We have a lot of high quality ...
Breaking Medicine News(10 mins):Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2
... Report ... July 24 Are you an e-patient?,Studies show that ... information. Thanks to Web 2.0, e-patients now have even ... care and learn about,advanced medical technologies. Go to ...
... helps those with HIV who become treatment-resistant, study shows ... offers more evidence that a new AIDS drug brings ... , The drug, known as raltegravir (Isentress), almost doubles ... virus despite being immune to other medications, according to ...
... HTH Worldwide, a global health and,safety services ... its,CityHealth(R) Profiles to Living Abroad.com and its multi-national ... to trusted,medical care in hundreds of destinations around ... information for those living,overseas or about to be ...
... Health and nutrition researcher Frank,Ervolino, ND, investigated ... the risks associated with stimulants. He reports that,Appetite ... Zurich,Pharmaceuticals, makes novel use of an established ingredient ... to lose weight. In fact, in the,U.S., where ...
... the University of Warwick, Dartmouth College, and the University ... influenced by the weight of those around them. Without ... keep up with the weight of the Joneses. For ... of imitative obesity. The researchers will present their results ...
... adoption of interoperable Health Information Technology (HIT) will ... in the U.S. healthcare system," Yul D. Ejnes, MD, ... on Health today. "Unfortunately, without adequate financial incentives, ... the technological curve." Dr. Ejnes, a member of the ...
Cached Medicine News:Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4Health News:Drug Holds Promise Against AIDS 2Health News:HTH Worldwide to Provide International Health Guide to Living Abroad.com 2Health News:New Natural Product from Zurich Pharmaceuticals Downs Appetite 2Health News:Research says fat friends and poor education helps people think thin 2Health News:ACP says Medicare should increase payments for physicians that use HIT to improve quality 2
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... VIVUS, Inc. (Nasdaq: VVUS ) today announced ... Drug Administration (FDA) for the New Drug Application (NDA) for ... meeting occurred on January 19th at the FDA,s offices in ... and VIVUS, management and consultants.  At this meeting the FDA ...
... D. Clark Turner, PhD, President and CEO of Aribex, Inc., ... in a ceremony Tuesday night at Discovery Gateway. Utah Governor ... others for providing distinguished service that has benefited the State ... be recognized among the other accomplished individuals who are receiving ...
Cached Medicine Technology:VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3Aribex CEO Receives Utah Governor's Medal 2
... the new large power line ... function as both cordless AND ... in flexibility. Its the versatility ... with the security of the ...
... consists of a pistol-grip handpiece available in ... wide range of couplers that can be ... applications., ,MicroAire SmartDriver. Modular Pistol-Grip instrument ... different module for drilling, pinning, cutting, and ...
... Meniscus Implant (CMI) is a type I ... irreparable meniscus tear or loss of meniscus ... procedure. The purpose of the CMI ... and return to a more vigorous lifestyle, ...
... The MicroAire Carpal Tunnel Release System ... surgery. This innovative system, using a minimally-invasive ... small incision at the base of the ... assembly. An endoscope, connected to a standard ...
Medicine Products: